AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
2.05
+0.02 (1.23%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.00 - 2.05
52 week 1.55 - 5.75
Open 2.05
Vol / Avg. 160,081.00/454,783.00
Mkt cap 103.19M
P/E     -
Div/yield     -
EPS -1.12
Shares 50.34M
Beta 2.96
Inst. own 33%
Nov 9, 2017
Q3 2017 AcelRx Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -875.12% -248.64%
Operating margin -595.90% -184.12%
EBITD margin - -172.29%
Return on average assets -64.87% -37.89%
Return on average equity - -310.75%
Employees 39 -
CDP Score - -

Address

351 Galveston Dr
REDWOOD CITY, CA 94063-4736
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Richard A. King President
Age: 52
Bio & Compensation  - Reuters
Vincent J. Angotti Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Raffi M. Asadorian Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 52
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wright-Mitchell Chief Legal Officer
Age: 46
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 61
Bio & Compensation  - Reuters
Howard B. Rosen Director
Age: 59
Bio & Compensation  - Reuters